| Care One At Millbury | |
| 312 Millbury Avenue, Millbury, Massachusetts 01527 | |
| (508) 793-0088 | |
| Name | Care One At Millbury |
|---|---|
| Location | 312 Millbury Avenue, Millbury, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 154 |
| Occupancy Rate | 79.09% |
| Medicare ID (CCN) | 225720 |
| Legal Business Name | 312 Millbury Avenue Operating Company, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1942209721 |
| Organization Name | 312 MILLBURY AVENUE OPERATING COMPANY, LLC |
| Doing Business As | MILLBURY HEALTH CARE CENTER |
| Address | 312 Millbury Avenue, Millbury, MA 01529 |
| Phone Number | 508-793-0088 |
News Archive
When a large group of children with aggressive behavior experienced devastating tornadoes, many of those with higher anxiety showed greater resilience, according to a study published online in the Journal of Clinical Child & Adolescent Psychology, published by the Society of Clinical Child and Adolescent Psychology.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy which was submitted in May 2011.
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.
Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
When a large group of children with aggressive behavior experienced devastating tornadoes, many of those with higher anxiety showed greater resilience, according to a study published online in the Journal of Clinical Child & Adolescent Psychology, published by the Society of Clinical Child and Adolescent Psychology.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy which was submitted in May 2011.
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.
Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 8.12 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.12 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 68.53 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.83 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.94 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 8.66 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.08 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 93.83 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.22 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.88 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.14 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 24.92 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.67 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.52 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.79 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 83.76 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 97.43 | 82.93 |
News Archive
When a large group of children with aggressive behavior experienced devastating tornadoes, many of those with higher anxiety showed greater resilience, according to a study published online in the Journal of Clinical Child & Adolescent Psychology, published by the Society of Clinical Child and Adolescent Psychology.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy which was submitted in May 2011.
AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe and effective HIV vaccine.
Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, reported on its results for the fourth quarter ended and full year ended December 31, 2014.
› Verified 2 days ago
Care One At Millbury Location: 312 Millbury Avenue, Millbury, Massachusetts 01527 Phone: (508) 793-0088 |